Novel multispectral optoacoustic tomography contrast agents for evaluation of early response to radiation therapy

项目摘要/摘要 血管灌注是评估许多病理状态的有用生物标志物。我们的研究将 专注于开发用于动态增强(DCE)的高级造影剂。 光谱光声层析成像(MSOT；也称为光声成像(PAI))用于定量 测量这一参数的变化以测量实体瘤对放射治疗的早期反应。这 新兴的成像技术提供了卓越的时间分辨率，这对于估计动力学 灌注率高，同时还提供出色的空间分辨率。然而，现有的造影剂用于这种情况 成像方式具有严重的性能限制。涅槃科学公司提议开发一种新的 DCE MSOT中性能增强的造影剂。这将包括修改现有的 疏水设计，以优化其在体内的水溶性、生物相容性和生物分布属性 使用。涅槃试剂在近红外(NIR)光谱窗口中具有尖锐而狭窄的吸收带， 提供首个用于多路成像的光谱可分辨窄谱试剂的多色调色板 具有更高的敏感度。这些造影剂将为超声心动图的评价提供突出的创新。 DCE MSOT的肿瘤血流灌注变化可提示对放射治疗的早期反应。

Project Summary/Abstract Vascular perfusion is a useful biomarker for assessment of many pathological conditions. Our research will focus on development of superior contrast agents for use with Dynamic Contrast Enhanced (DCE) Multi- Spectral Optoacoustic Tomography (MSOT; also known as photoacoustic imaging (PAI)) to quantitatively measure changes in this parameter to measure early response of solid tumors to radiation therapy. This emerging imaging technology provides outstanding temporal resolution that is critical for estimating kinetic perfusion rates while also providing excellent spatial resolution. However, existing contrast agents for this imaging modality possess serious performance limitations. NIRvana Sciences, Inc. proposes to develop a new contrast agent with enhanced performance in DCE MSOT. This will include modification of existing hydrophobic designs to optimize their water solubility, biocompatibility, and biodistribution attributes for in vivo use. NIRvana’s agents possess sharp, narrow absorption bands in the near-infrared (NIR) spectral window and offer the first multi-color palette of spectrally resolvable narrow spectrum agents for multiplex imaging with MSOT with greater sensitivity. These contrast agents will provide outstanding innovations for evaluation of changes in tumor perfusion by DCE MSOT that can indicate an early response to radiation therapy.